AXA Partners Signs With Upptec to Automate the Claims Process
19.10.2021 09:00:00 EEST | Business Wire | Press release
AXA Partners Germany and the Swedish-based Insurtech company Upptec will partner up for AXA Partners claims automation roll-out. The partnership will be the first of its kind in Germany and the data-driven claims valuation will center around all household electronics for its initial implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005815/en/
AXA Partners Signs With Upptec to Automate the Claims Process (Graphic: Business Wire)
Upptec has implemented claims automation within home contents in most parts of Europe, but this will be the first customer in Germany to roll-out data-driven and automated claims valuation for electronics based on real time local data with full automation capabilities.
“We as AXA Partners are delighted to announce the integration of Upptec’s valuation solution into our claims process. This will allow us to quickly support our customers in replacing their most valued possessions directly to their home and bring the customer experience to the next level. We look forward to working with Upptec to optimize and automate claims handling in the German market for the benefit of the policyholder.” — explains Kirsten Wenz, TPA Manager Consumer Electronics, AXA Partners Germany.
“We are extremely proud to be delivering a claims valuation solution with real-time responses from the local market for AXA Partners. This is the start of a partnership with great potential, and we see many common objectives by digitizing and automating the claims process, - making it transparent, objective and fast for the German policyholders that will set new standards for digital claims in Germany.” – says Magnus Franck, CEO at Upptec.
About AXA Partners Germany
AXA Partners is part of the international AXA Group, headquartered in Paris, and is one of the world's leading assistance and insurance providers worldwide. With more than 1000 business partners all over the world AXA Partners is working on innovative solutions for more security and a better quality of life. Worldwide, AXA Partners has more than 9000 employees. With this strong network and service partners in more than 200 countries, AXA Partners provides its customers with reliable support in the event of a claim — around the globe, 24 hours a day, 365 days a year.
For more information visit: www.axapartners.de
About Upptec
Upptec wants to transform the world’s insurance industry by making digital claims simple, fast, and effortless. From the first notice of loss to settlement, we automate the claims processes. Since the start Upptec have reduced costs, increased efficiencies, and driven circularity in a sustainable way-of-thinking for partners and customers while at the same time providing the best digital consumer centric experience.
For more information visit: https://upptec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005815/en/
Contact information
Press Contact - Upptec
Matilda Hansson
Upptec AB
pr@upptec.com
Press Contact – AXA Partners
Roxana Müller
AXA Partners | AXA Assistance Deutschland GmbH
presse@axa-assistance.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
